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Abstract
Environmental changes affecting the relationship between the developing immune system and microbial exposure have
been implicated in the epidemic rise of allergic disease in developed countries. While early developmental differences in T
cell function are well-recognised, there is now emerging evidence that this is related to developmental differences in innate
immune function. In this study we sought to examine if differences associated with innate immunity contribute to the
altered immune programming recognised in allergic children. Here, we describe for the first time, the association of carriage
of the T allele of the tagging single nucleotide polymorphism rs12979860 3 kb upstream of IL28B, encoding the potent
innate immune modulator type III interferon lambda (IFN-l3), and allergy in children (p = 0.004; OR 4.56). Strikingly, the
association between rs12979860 genotype and allergic disease is enhanced in girls. Furthermore, carriage of the T allele at
rs12979860 correlates with differences in the pro-inflammatory profile during the first five years of life suggesting this
contributes to the key differences in subsequent innate immune development in children who develop allergic disease. In
the context of rising rates of disease, these immunologic differences already present at birth imply very early interaction
between genetic predisposition and prenatal environmental influences.
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Introduction
The threat of premature death caused by infectious diseases in
developed countries has largely past since the widespread introduc-
tion of antibiotics and improved standards of personal cleanliness, yet
paradoxically contemporary communities are now beset by a
dramatic increase in the burden of chronic inflammatory diseases.
This clearly highlights the susceptibility of the immune system to
modern environmental changes [1]. Not only allergic conditions such
as asthma, allergic rhinoconjunctivitis, food allergies and eczema are
on the rise but autoimmune disorders (such as type 1 diabetes and
chronic inflammatory bowel disease) as well as neurodegenerative
and cardiovascular diseases [1], are now following the same alarming
trends [2]. While complex lifestyle changes are driving this surge in
disease, genetic factors are critically important in determining the
susceptibility to environmental changes that can enhance inflamma-
tory responses, and the predisposition to these diverse inflammatory
diseases [1]. Furthermore, the rising rates of allergic disease in
infancy clearly indicates that early gene-environment interactions,
even before birth, play an important role in determining suscepti-
bility to inflammation and immune disease [3].
Prospective longitudinal case-control comparisons of immune
development in well-characterized children provide opportunities
to assess development of innate inflammatory responses in
relationship to genetic and clinical phenotype. Using this
approach, our initial studies [4,5] revealed striking differences in
the biological responses (to microbial products) of children who
develop allergic disease. These children show increased inflam-
matory (IL-6, IL-1b and TNFa) cytokine production at birth and
during their neonatal period, compared to children that remain
non-allergic [4,5] and this is associated with subsequent propensity
for allergic Type 2 adaptive responses [5]. Plasmacytoid dendritic
cells (pDC) from these allergic children express high levels of
bacterial recognition receptor, toll like receptor (TLR)2, during
their first year of life compared to non-allergic controls [5]. In the
children with allergy high expression of TLR2+ on pDCs was
strongly associated with a distinct innate immune response and
allergic disease phenotype.
This new evidence that susceptibility to allergy may be
associated with an altered innate immune development from birth
prompts more detailed examination of underlying candidate
pathways. Given clues that pDC function, which is pivotal in
translating distinct innate stimuli into robust type I and III
interferon (IFN) production, is affected in allergic children, we
hypothesised that an alteration in the biology of type I and/or type
III IFN might also be affected.
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The newly discovered type III IFN family is composed of three
closely related molecules in humans: IFN-l1 (IL29), IFN-l2
(IL28A), and IFN-l3 (IL28B) that exhibit anti-viral activity [6] via
a similar but likely independent mechanism to type I IFNs. These
molecules are likely to have an immunomodulatory function as
studies have shown that IFN-l1-treated human DCs can induce
proliferation of suppressor T cells [7], inhibit in vitro naı¨ve and
memory IL-13 responses in human T cells [8,9], augment antigen-
specific IFNc release [10], and upregulate TLR expression and
their response to ligands [11]. Support for the role of IFN-l in
allergic disease can be extrapolated from relatively few studies that
have examined their role in allergic asthma. Contoli and
colleagues have shown that deficient IFN-l induction (IFN-l1
and IFN-l2/3) by viral (rhinovirus) and bacterial (lipopolysaccha-
ride) stimuli was associated with severity of asthma exacerbations
in allergic asthmatics [12]. A recent study clearly demonstrated
that IFN-l2 can effectively induce type 1 immunity and suppresses
Th2 immunity and consequently allergic airway disease in a
mouse model of allergic asthma via its action on DCs [13].
Furthermore, genetic variations in IL28B (IFN-l3) have been
linked with differential expression of interferon-stimulated genes
(ISG) in patients with chronic Hepatitis C [14,15] and with their
outcome of IFN-a therapy [16,17]. Although the IFN-l family
comprises of the three related members, IFN-l3 is to date the only
member with genetic variations associated with differential
expression profiles for downstream genes involved in the immune
response and outcome for a disease that exhibits symptoms of
dysregulation of the immune response. Accordingly, in this study
we set to examine the relationship between IL28B genetic
variation and allergic disease in children.
Results
Genetic variation at the tagging SNP rs12979680 3 kb
upstream of IL28B is associated with risk of allergic
disease
We present data showing support for IL28B playing a role in
allergic disease. We genotyped 70 children (35 allergic and 35 non-
allergic; Cohort 1) for the tagging SNP rs12979860 that resides
3 kb upstream of IL28B. Carriage of the T allele at rs12979860
has previously been shown to be highly predictive of poor
Hepatitis C virus (HCV) infection and treatment outcome [16–
19]. Here, presence of the T allele at rs12979860 was over-
represented in children with allergic disease (p = 0.004; OR=4.56,
CI 1.7–12.6) (Fig. 1a). Although the frequency of the C allele was
lower in allergic children compared to non-allergic children (0.6 vs
0.8, respectively) the strongest predictor of allergic disease was
carriage of the T allele. The odds ratio obtained for this
relationship (OR=4.6) is akin to what was observed in a recent
study examining the relationship between IL28B and HCV
infection outcome in a single source cohort of similar size
(OR=4.1) (Fig. 1b). The single source cohort comprises women
who were exposed to HCV contaminated immunoglobulin D in
Ireland in the 1970s and inherently controls for ascertainment
bias, clinical, demographic and viral factors that allow the optimal
platform to assess the IL28B genetic contribution to HCV
outcome. In studies that cannot account for these factors, the
odds ratios obtained for the association of IL28B variants and
HCV outcome are much lower (OR=3.0 vs OR 4.1 and 7.4) [20].
In this study, the strict criteria used to assess allergic and non-
allergic (non-atopic) children removed several confounding factors
that allowed a better assessment of host genetic contribution to
allergic disease. As sensitisation against environmental allergens in
the Australian population is highly prevalent, the criteria used to
select non-allergic children is critical and in this cohort selection
for non-atopic children was based on an extensive array of clinical
tests over the first five years of life; a critical period of immune
ontogeny. Conservative assessment of the phenotype definition
can offset the value of larger sample size in disease gene association
studies [21]. Accordingly, the robust relationship we find between
IL28B and allergic disease in a relatively small sample size suggests
that IL28B (and effects on IFNl-3 levels) is likely to play a
dominant role in the susceptibility and development of allergic
disease. These results are comparable to what has been reported
for HCV infection and treatment outcome in which it is well
established that IL28B variants are the strongest host genetic
contributor to HCV outcome.
Figure 1. Variation at tagging SNP rs12979860 confers risk for allergic disease. a. Carriage of the T allele of rs12979860 is over-represented
in children with allergic disease (cohort 1, n = 70) (p = 0.004). This relationship is also observed for children with IgE-mediated food allergy (Cohort 2,
n = 60) (p = 0.04 dominant model). For both cohorts, the frequency of the different genotypes varies between disease and control subjects (p = 0.02;
cohort 1 and cohort 2). b. Odds ratio (OR; 95% CI) for carriage of T allele of rs12979860 and allergic disease and for HCV persistence. Odds ratio values
for HCV cohorts are from di Iulio et al [20] and Tillman et al [28]. ORs for allergic disease and food allergy adjusted for gender. ORs for HCV cohorts
adjusted for HBV co-infection in all cohorts and gender in the multiple source cohort.
doi:10.1371/journal.pone.0030607.g001
IL28B and Allergic Disease in Children
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30607
Association between rs12979860 genotype and food
allergy: Validation of genetic association in food allergic
cohort
We then extended our analysis between allergic phenotype and
carriage of the T allele at rs12979860 to a second paediatric
cohort (n = 30; Cohort 2) in which subjects were defined as
clinically food allergic. These subjects were recruited from the
same clinic and therefore have similar demographic character-
istics as Cohort 1. When we compared these subjects to the
screened non-allergic subjects (controls) as described above we
found that carriage of the T allele at rs12979860 is also associated
with food allergy (p = 0.04; OR=3.0, CI 1.8–5.2) (Fig. 1b).
Interestingly for Cohort 2 but not Cohort 1, the frequency of the
homozygote T/T genotype was higher than observed in the non-
allergic children (Fig. 1a). Accordingly, all subsequent analyses
performed on Cohort 1 examined the influence of carriage of the
T ‘‘risk’’ allele.
Association of rs12979860 genotype with allergic disease
increases with age
In order to assess the impact of IL28B on early allergic
phenotype, we examined the association of rs12979860 genotype
with allergic outcome during early childhood using subjects in
Cohort 1, as detailed clinical data on these subjects had been
collected from follow-up visits during the first five years of life.
There is a clear association between carriage of the T allele of
rs12979860 and development of early allergic disease, particu-
larly for sensitization against environmental antigens and IgE-
mediated food allergy (Fig. 2). In the case of atopic dermatitis,
there is a trend for discrimination between the rs12979860
genotype during the first year of life and this becomes significant
from 2.5 years of age (Fig. 2). Clear diagnosis of asthma cannot
be determined during the first year of life however carriage of
the T allele is significantly associated with asthma diagnosis by
age 5.
Figure 2. Carriage of the T allele of rs12979860 is associated with clinical presentation of allergic disease. Proportion of infants in
cohort 1 that are sensitised, have doctor-diagnosed atopic dermatitis, asthma or IgE-mediated food allergy at 1, 2.5 or 5 years of age, with C/C (n = 35,
black bars) or C/T, T/T (n = 35, grey bars) genotype. OR= odds-ratio. *P,0.05, **P,0.01 and ***P,0.001 versus age-matched C/C genotype.
doi:10.1371/journal.pone.0030607.g002
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Gender bias in the association of rs12979860 genotype
with allergic disease
There is a significant interaction between gender and carriage
of the T allele of rs12979860 for allergic disease (P = 0.04). The
effect is particularly evident for sensitization (Fig. 3a top) and to a
lesser extent for atopic dermatitis (Fig. 3a bottom) but not for
asthma or IgE-mediated food allergy during early childhood (data
not shown). Interestingly, it was only amongst females that we
found differential trends in allergy status with age relative to
rs12979860 genotype. Carriage of the T allele of rs12979860 in
females but not males was associated with increased risk of
sensitisation with age (P = 0.02; Fig. 3b). Conversely, amongst
females with the C/C genotype we see a reduction in the
proportion with atopic dermatitis with age (P= 0.04; Fig. 3b).
rs12979860 genotype correlates with innate immune
function
We then examined the association between TLR-mediated
innate immune function (namely IL-1B, TNF alpha cytokine
production after TLR ligation with classical model ligands [5]) and
rs12979860 genotype. We have previously shown a differential in
the level of pro-inflammatory cytokine production after cord blood
stimulation with select TLR ligands is associated with either
allergic and non-allergic status in later life [5]. Briefly, children
with allergic disease have higher levels of pro-inflammatory
cytokines at birth (in cord blood) and during their early postnatal
period, however this responsiveness declines with age and by pre-
school age (5 years) is significantly depressed compared to age-
matched non-allergic controls. In non-allergic children, TLR
responses mature with age, which is necessary to elicit appropriate
responses to pathogens. Here we show that this key difference in
immune ontogeny is significantly associated with rs12979860
genotype and can be seen after the stimulation with the majority of
TLR ligands (Fig. 4). In general, subjects with the C/C genotype
(solid lines) are characterised by significantly lower levels of pro-
inflammatory cytokine production at birth after TLR-dependent
stimulation (exception being TLR8). For these individuals with the
C/C genotype, a postnatal increase in IL-1b and TNF-a
production following TLR stimulation (most pronounced for
TLR2, 3, 4 and 7) is observed (Fig. 4). These findings are
contrasted by the profile of TLR-dependent cytokine responses in
children carrying the T ‘‘risk’’ allele (that is, C/T or T/T
genotype; dashed lines) (Fig. 4), which shows high levels of pro-
inflammatory cytokines at birth (in cord blood) in response to TLR
ligation. Furthermore, TLR-induced pro-inflammatory cytokine
responses in these children decline with age (in particular TNF
production). These findings are consistent with our previous
Figure 3. Gender differences in the association between carriage of the T allele of rs12979860 and allergic disease. a. Interaction
between gender and carriage of the T allele of rs12979860 for sensitization (top panel) and atopic dermatitis (bottom panel) in cohort 1 in individuals
with C/C (n = 35, black bars) or C/T,T/T (n = 35, grey bars) genotype. *P,0.05 and **P,0.001 versus females with C/C genotype. b. Trends in
sensitization (top panel) and atopic dermatitis (bottom panel) levels with age relative to rs12979860 genotype. *P,0.05 versus proportion of
sensitised females with C/C genotype and {P,0.05 versus C/T,T/T genotype in females with atopic dermatitis. OR= odds ratio.
doi:10.1371/journal.pone.0030607.g003
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observation in the same cohort showing a similar distinguishing
pattern in cytokine profiles in allergic and non-allergic during the
maturation of the immune system over the first five years of life
[5]. Although this can be seen in male and female children, these
trends are most pronounced in females with the C/C genotype
(Fig. 4).
Discussion
Allergic disease is a complex trait with a substantial genetic
contribution likely involving a number of different genes, gene-
gene interactions and environmental influences. However, iden-
tifying the causative genes involved in the susceptibility and
progression of allergic disease is hampered by heterogeneity in
clinical phenotype, incomplete penetrance, typical modest or low
genetic effect size of a single causative gene and the often
immeasurable interaction between genes and the environment.
Importantly, phenotypic definition is a critical factor to consider in
association studies to optimise the ability to identify new genetic
associations with disease [21]. In this study, the use of stringent
criteria to define allergic and non-allergic children during the
critical five-year follow-up from birth has resulted in a clinically
well-differentiated disease and control group that should facilitate
the identification of putative causative genes in allergic disease.
Our previous studies have clearly shown a different develop-
mental trajectory for innate immune function between allergic and
non-allergic children during early childhood [4,5]. Given the likely
role of pDCs and IFNs in this framework, we investigated the role
of genetic variations in IL28B in allergic disease. We show for the
first time a strong association between genetic variations flanking
and within IL28B and allergic disease. The effect of IL28B
variations on atopy risk may be one of the strongest genetic
predictors of allergic disease as most other candidate genes for
allergic disease appear to have only a modest effect size.
Interestingly, of more than a dozen genome-wide scans performed
on atopic disease (including atopy, asthma and atopic dermatitis)
none have highlighted this chromosomal region (www.genome.
gov/gwastudies) as has been done for HCV infection and
treatment outcome. This may be best explained by the clinical
difficulty in phenotyping atopic and non-atopic subjects (particu-
larly children) included in previous studies, given the high rate of
atopy even in non-symptomatic subjects.
As an interesting analogy, HCV clearance (natural and
treatment-induced) is associated with the C/C ‘‘protective’’
genotype of rs12979860 with a similar effect size. It currently
remains speculative if the C/C genotype leads to higher or lower
levels of IFN-l (and specifically IFN-l3) secretion (locally and
systemically). Some studies have suggested that the C/C genotype
is associated with diminished ISG expression (albeit mainly for
liver and in HCV-infected subjects) [14,15]. Others have shown
higher levels of IFN-l in plasma in individuals who carry the C
allele of rs12979860 (C/C and C/T subjects) [22]. Interestingly,
subjects with autosomal dominant STAT3 deficiency (Hyper IgE
syndrome) [23], which may lead to mutations in the IFN-l
signalling pathway, present with atopic dermatitis and high levels
of IgE in serum. Thus, one could speculate that the C/T or T/T
genotype in allergic children is associated with lower levels of IFN-
l secretion. Furthermore, IFN-l is thought to suppress Th2-type
immune responses, which are the hallmark of allergic disease. This
is further supported by the recent study by Koltsida and colleagues
who showed that IFN-l can promote Th1 immunity and suppress
Th2 responses in the mouse model of allergic asthma [13]
initiating suggestions that IFN-l could be used as a new treatment
approach for allergic asthma [24]. In this study, we have
demonstrated a relationship between higher levels of a pro-
inflammatory cytokine profile at birth with diminished levels of
these cytokines over time in children who carry the T allele of
rs12979860 with an inverse relationship observed for children with
the ‘‘protective’’ C/C genotype. However, levels of IFN-l3 at
relevant sites for atopic disease have not been established and the
role of IFN-l3 in IgE-mediated diseases and in the Th1/Th2
balance remains of great interest.
Frequencies of the rs12979860 alleles vary across populations
with Africans having a higher frequency of the T ‘‘risk’’ allele than
Caucasians and Asians [19]. In HCV infection and treatment
outcome, frequency of the T allele of rs12979860 correlates with the
known disparity in responses in different populations [19]. In
allergic disease, it is known that there are differences in the
prevalence and disease progression of allergic disease in populations
[2] with African Americans shown to have much higher rates of
death from asthma. A better link between IL28B allele frequencies
and epidemiological studies may reveal how much IL28B variation
contributes to ethnic disparities in the prevalence of atopic disease.
Here, we also clearly show a gender bias in the ‘‘protective’’
effect of the C/C genotype of rs12979860 in females compared to
males in atopic disease. The gender bias extends to the
relationship between rs12979860 and innate immune function.
The reasons for this gender bias are not clear but may involve
differential transcriptional control or hormonal responsiveness of
relevant genes. Interestingly, female gender is also a predictor of
favourable HCV infection outcome [25].
In view of the increasing burden of allergic disease in clinical
practice, novel biomarkers that can be used for risk stratification of
challenges, treatment and diet advice are invaluable. Definition of
the IL28B genotype in children will allow the rapid identification
of those children that are at risk of developing allergic disease and
therefore management/intervention can be optimised accordingly.
Overall, analysing the IL28B genotype is a simple cost-effective test
that can be automated and already has been optimised for clinical
practice as a predictive factor for outcome of HCV infection.
In conclusion, despite a proposed linkage between the level of
environmental pathogenic exposure and allergy (hygiene hypoth-
esis) no clear mechanistic linkage has been proposed that might
explain the apparent enhanced susceptibility. Here for the first
time we show that genetic variants in an innate microbial defence
pathway (IL28B) are highly predictive of allergic disease with clear
gender bias, and directly correlated with the innate immune
function. These findings have broad-ranging implications for
understanding the pathogenesis of not only allergic disease but
many other inflammatory and autoimmune diseases.
Methods
Subjects
All children were recruited ante-natally from healthy pregnant
mothers from obstetricians in Perth, Australia. Children were
Figure 4. IL-1B and TNF cytokine production with age in peripheral blood mononuclear cells from individuals with C/C or C/T,T/T
genotype stimulated with TLR agonists. Plots are scaled to span ,90% of the data range. Differences between groups with p-values,0.05 are
annotated: CB measures of rs12979860 genotype C/T, T/T vs C/C amongst females (*: P#0.01) and males (#: P#0.01); average linear trend of profiles
of C/T,T/T vs C/C amongst females ({: P#0.01, {{: P#0.001) and males ({: P#0.01, {{: P,0.001).
doi:10.1371/journal.pone.0030607.g004
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selected from 739 children enrolled in prospective birth cohorts
designed to examine allergy pathogenesis. The first cohort (Cohort
1) consisted of 35 allergic and 35 non-allergic infants, which were
followed from birth to age 5 years to assess their development of
innate immune function and are described elsewhere [5]. Children
were defined as non-allergic if they had no history of sensitisation
or allergic disease at any age (based on at least 2 follow-up visits),
or allergic if they have had a doctor-diagnosis of atopic dermatitis,
allergic rhinitis, food allergy or asthma, and specific IgE to
allergens as detected by a skin-prick test (SPT) at one or more
clinic visits. Cohort 2 consisted of children with doctor-diagnosed
food allergy (n = 30) recruited from the same research clinic as
Cohort 1. IgE-mediated food-allergy was defined as a history of
immediate symptoms after contact with food, ingestion of food, or
both and a positive SPT to that food. Symptoms of acute food
allergy included skin reactions (hives, rash, or swelling) and/or
respiratory tract symptoms (cough, wheeze, or stridor) and/or
gastrointestinal symptoms (abdominal pain, vomiting, or loose
stools) and/or cardiovascular symptoms (collapse). In this cohort,
12/30 (40%) had severe food allergy (resulting in anaphylaxis). 27/
30 (90%) had allergy to eggs, 13/30 (43%) allergy to nuts, 7/30
(23%) were allergic to house dust mite, 5/30 (17%) to cat dander
and 20/30 (67%) reacted to multiple foods. Subjects in Cohort 1
and 2 were all of Caucasian ethnicity.
Ethics statement
Written, informed consent from the next of kin, carers or
guardians on the behalf of the children participants was obtained
for this study. Ethics approval was given by Princess Margaret
Hospital Ethics Committee (EC07-74) and contributing Centres
(EC2004/005). The protocol and the procedures of the study were
conducted in conformity with the ethical guidelines of the
Declaration of Helsinki.
IL28B Genotyping
Genotyping of the tagSNP rs12979860 upstream of IL28B on
subjects in both cohorts was performed by TaqMan allelic
discrimination using the Custom Assay designed by Ge and
colleagues [16]. Typing of rs12979860 was performed by two
independent laboratories blinded to the clinical phenotype with
100% concordance. There was no significant deviation from
Hardy Weinberg equilibrium.
Further characterisation of the IL28B region was performed by
examining an additional set of putative causal SNPs (rs8403219,
rs28416813, rs8103142 and rs4803217) that reside within the
promoter, coding and 39 untranslated region of IL28B [20]. These
SNPs are in strong linkage disequilibrium with rs12979860 and
define the two main haplotypes of the block encompassing IL28B,
with the type II haplotype containing the minor or ‘‘risk’’ allele(s)
for at least one of the putative causal SNPs. As there was complete
linkage disequilibrium between rs12979680 and the type II
haplotype in all subjects, the p-value and OR were the same as
for carriage of the T allele of rs12979860. Genotyping of the
additional four SNPs within IL28B and another tagging SNP
rs8099917 10 kb upstream of IL28B on subjects in Cohort 1 and 2
was performed by TaqMan allelic discrimination using Custom
Assays and Assay on demand provided by Applied Biosystems as
described by di Iulio et al [20].
Statistical analyses
Logistic regression was used to assess relative effects of genotype,
gender and age on allergy status. Confidence intervals for odds
ratios (OR) were obtained by exponentiating the 95% confidence
interval for the log odds, estimated by the model coefficient, and p-
values were determined by a Wald test. Multivariable models
provided adjusted estimates and enabled assessment of variable
interactions. Evaluation of trends in allergy status over age
accommodated the within-individual correlations by assuming an
autoregressive structure within a generalized estimating equation
framework.
Cytokine measures were log-transformed prior to analysis to
ensure approximate normality of residuals about mean values.
Differences in baseline (cord blood) measures were assessed by
standard linear regression. Mixed effect linear regression models
were utilized for estimation of group-average changes in the
measures over time since birth, and assessment of genotype and
gender effects on the linear trend [26,27]. The models assumed an
autoregressive correlation structure for accommodation of the
within-individual dependencies. All statistical analyses were
carried out using TIBCO Spotfire S+ 8.2 for Windows (TIBCO
Spotfire Inc, Palo Alto 2010).
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